鄰近類別 圖書 [1/1] 期刊論文 [327/330] 類別統計 近3年內發表的文件:16(8.94%) 含全文筆數:115(64.25%) 文件下載次數統計 下載大於0次:115(100.00%) 下載大於100次:112(97.39%) 檔案下載總次數:39303(22.07%) 最後更新時間: 2024-12-01 07:53 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Risk of type 2 diabetes mellitus an... Phase 1 studies of D07001-F4 and D0... Updated overall survival (OS) from ... Outcomes of post-immunotherapy dura... Updated overall survival (OS) from ... Updated results of the FOENIX-CCA2 ... Comparative genomic analysis and it... A phase II trial of nivolumab, gemc...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目126-150 / 179. (共8頁) << < 1 2 3 4 5 6 7 8 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2013-05	Impact of virologic factors on recurrence-free survival in HBV-related hepatocellular carcinoma after surgical resection: Post hoc analysis from a prospective study with long-term follow-up	Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number e15032.
2013-03	Auy922, a novel Hsp90 inhibitor effective against ABC-dlbcl and malt lymphoma cells harboring genetic alteration-associated NF-kappa B activation	Annals of Oncology. 2013 Mar;24(Suppl. 1):24-25.
2012-11	Blockage of Nrf2/AKR1C axis enhanced therapeutic efficacy of oxaliplatin in oxaliplatin resistant gastric cancer cells	European Journal of Cancer. 2012 Nov;48(Suppl. 6):48.
2012-10	Front-line antibiotic therapy in early-stage H. Pylori-positive gastric Diffuse Large B-Cell Lymphomas with or without malt features	Annals of Oncology. 2012 Oct;23(Suppl. 11):105.
2012-09	Heat shock protein 90 inhibition downregulates c-Kit expression in gist cells through diminishing transcription and enhancing protein degradation via both autophagy and proteasome pathways	Annals of Oncology. 2012 Sep;23(Suppl. 9):538.
2012-09	Detection of caga expression in gastric mucosa-associated lymphoid tissue lymphoma-biologic significance and clinical implication	Annals of Oncology. 2012 Sep;23(Suppl. 9):351.
2012-05-20	Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial	Journal of Clinical Oncology. 2012 May 20;30(15 Suppl.):Abstract number TPS4149.
2012-03	Involvement of autophagy in endogenous and NVP-AUY922-induced C-kit degradation in both imatinib-sensitive and -resistant gastrointestinal stromal tumor cells	Annals of Oncology. 2012 Mar;23(Suppl. 1):28.
2012-02	Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy	Journal of Clinical Oncology. 2012 Feb;30(4):613.
2011-11	Role of chromogranin a and neuron-specific enolase biomarkers in progression-free survival (PFS) with everolimus (EVE) versus placebo (PB) in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III radiant-3 results	Neuroendocrinology. 2011 Nov;94(Suppl. 1):37.
2011-09	B cell-activating factor of TNF family (BAFF) signaling pathway is associated with Helicobacter Pylori-independent growth of gastric MALT lymphoma without T(11;18)(q21;q21)	European Journal of Cancer. 2011 Sep;47(Suppl 1):S648-S649.
2011-09	Phase II study of low-dose everolimus plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for first-line treatment of metastatic or recurrent gastric cancers	European Journal of Cancer. 2011 Sep;47(Suppl 1):S467.
2011-05	Novel Hsp90 inhibitor NVP-AUY922 downregulates mutant c-Kit protein through transcription and enhancing protein degradation via both proteasome and autophagy-mediated pathways	Drug Metabolism Reviews. 2011 May;43(Suppl. 1):78-79.
2011-04	Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas	Cancer Research. 2011 Apr;71:Abstract number 1701.
2011-02	Loss of ASS1 expression in myxofibrosarcoma via promoter hypermethylation: Prognostic and potential therapeutic implications	Laboratory Investigation. 2011 Feb;91:17A.
2011-02	Loss of ASS1 expression in myxofibrosarcoma via promoter hypermethylation: Prognostic and potential therapeutic implications	Modern Pathology. 2011 Feb;24(Suppl. 1):17A-18A.
2011-02	A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer	Journal of Clinical Oncology. 2011 Feb;29(4):Abstract Number 237.
2011-02	Phase II study of weekly low-dose everolimus plus weekly 24-hour infusions of cisplatin and high-dose 5-fluorouracil and leucovorin for first-line treatment in patients with advanced gastric cancers	Journal of Clinical Oncology. 2011 Feb;29(4):Abstract Number 86.
2011-02	Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma	Journal of Clinical Oncology. 2011 Feb;29(Suppl. 4 ):Abstract Number 6
2011-02	Effect of inhibition of heat-shock protein 90 on mutant c-Kit protein as modulated by mRNA expression and protein degradation through both proteasome and autophagy-mediated pathways	Journal of Clinical Oncology. 2011 Feb;29(Suppl. 4):Abstract Number 54
2010-11	Medical resources utilization of five most prevalent cancers in Taiwan (lung cancer, liver cancer, colorectal cancer, gastric cancer, and brest cancer): 2001 similar to 2007	Value in Health. 2010 Nov;13(7):A279.
2010-10	Nilotinib and sorafenib are more potent inhibitors for exon 11/17 C-kit mutants than sunitinib: results of incorporating cell-based screening platform and virtual molecular modeling study	Annals of Oncology. 2010 Oct;21(Suppl. 8):56-56.
2010-10	Combined modalities of resistance in a cisplatin-driven human betel-associated oral squamous cell carcinoma	Annals of Oncology. 2010 Oct;21(Suppl. 8):52.
2010-06	Randomized, phase 1 study of everolimus in patients with advanced hepatocellular carcinoma	Annals of Oncology. 2010 Jun;21(Suppl. 6):27.
2010-05	Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors	Journal of Clinical Oncology. 2010 May;28(15):Abstract Number e13024.

顯示項目126-150 / 179. (共8頁) << < 1 2 3 4 5 6 7 8 > >> 每頁顯示[10|25|50]項目